Connect with us

Health

Sterling Biopharma Launches Fejeron Blood Tonic, Seeks To Inspire Nigerians

Published

on

Sterling Biopharma Launches Fejeron Blood Tonic, Seeks To Inspire Nigerians

Olushola Okunlade Writes

The pharmaceutical firm, Sterling Biopharma Limited, has introduced a new product called Fejeron Blood Tonic into the Nigerian market to support the country’s about 66.8% economically active population.

Fejeron Blood Tonic contains iron, Vitamin B12, and folic acid, all essential components that help to facilitate adequate blood supply and replenishment to the body with vital vitamins while enabling a strong immune system.

Sterling Biopharma Launches Fejeron Blood Tonic, Seeks To Inspire Nigerians
Left-Right: Product Manager, Sterling BioPharma Limited Olumide Oluremi; Regional Sales Manager, Sterling BioPharma Limited; Olatubosun Tosin; Finance Controller, Segun Olalere; Chief Operating Officer, Bayo Adepoju and Chanel Manager, Olatusi Opeoluwa during the official media launch of Fejeron Blood Tonic in Lagos.

Speaking at the media unveiling in Lagos on Thursday, September 15, the Chief Operating Officer, of Sterling Biopharma Limited, Mr. Adebayo Adepoju, said that the nature of stress and fatigue that Nigerians encounter on a daily basis requires that their physical and mental well-being is well supported to function at it best and this is why Fejeron Blood Tonic is uniquely formulated for everyone regardless of age or gender.

“At Sterling Biopharma, we believe that everyone deserves to be able to buy simple prescription drugs without breaking the bank. This is why from the moment we entered the Nigerian market, and with our wide range of products, we have made our intentions clear and that is to make quality pharmaceutical products affordable for all Nigerians.

“So, Fejeron Blood Tonic is the latest proof of our commitment to this mission. Despite its premium quality, Fejeron, at the moment is one of the most affordable blood tonics you will find in the Nigerian pharma market, and this is deliberate. All Nigerians should be able to take care of themselves,” he said.

Left-Right: Product Manager, Sterling BioPharma Limited, Olumide Oluremi; Finance Controller, Segun Olalere; and Chief Operating Officer, Bayo Adepoju, during the official media launch of Fejeron Blood Tonic by Sterling BioPharma Limited, in Lagos, yesterday.

Since its market introduction, Fejeron has quickly become one of the well-sought-after new brands in the pharmaceutical category, and the Product Manager, Olumide Ogunremi, linked the warm embrace of the product to its quality and appeal to the needs of the Nigerians.

He said: “The quick acceptance of Fejeron Blood Tonic in Nigeria is not a surprise to us. The enthusiasm to try out the product and the return purchases across the biggest pharmaceutical markets in Nigeria validate the quality of the product and timeliness of its emergence.”

On what makes Fejeron Blood Tonic unique, Ogunremi promised that both the young and old will love the taste of Fejeron, adding that extra effort has also been put into ensuring that the product has less chance of causing common side effects like metallic after-taste, staining of the teeth; constipation, diarrhea, nausea, and others.

On the brand’s promise to Nigerians, the C.O.O noted that Fejeron Blood Tonic is driven by the belief that truly, health is wealth and they are out to promote this culture among Nigerians, standing by them on the journey to their individual accomplishments.

“We realise that the average Nigerian is aspirational and that explains why hard work is a way of life, regardless of class. However, every dreamer needs an enhancer, a cheerleader, and a support system, a role we are happy to play.

“That is why our online launch campaign is encouraging Nigerians across all socioeconomic classes to jump on our social media handles @myfejeron on Facebook, Instagram, and Twitter to tell their stories with emphasis on what drives them to aspire, using the hashtag #myfejeron.

“We want to celebrate the Naija spirit and all we are saying is that Fejeron feels your hustle and we are with you on your journey to greatness. We will constantly remind you to take care of yourself in order to achieve those lofty dreams. Our biggest assets are our customers and we hold you, dear,” he said.

Health

mPharma Donates Drugs Worth N35 Million To Hospitals In Nigeria

Published

on

mPharma Donates Drugs Worth N35 Million To Hospitals In Nigeria

Olushola Okunlade Writes

As part of its Corporate Social Responsibility,mPharma, Africa’s leading patient-centered technology-driven healthcare company, has donated drugs worth 35 million Naira (approx.$76,000) to government-owned public hospitals across four states in Nigeria, including Lagos, Delta, Rivers, and Abuja.

The donations were made to a select group of hospitals with high patient footfall, and that primarily provide care to low-income patients.

According to the Chief Executive Officer and Co-founder of mPharma, Gregory Rockson, the donated drugs are expected to be dispensed free of charge to patients suffering from a myriad of diseases including hypertension, diabetes, malaria, and infectious diseases who are unable to afford the medications needed for their treatment. The impact is expected to reach the underserved population who increasingly are unable to afford life-saving medications due to rising inflation and its associated unfavorable economic conditions.

mPharma Donates Drugs Worth N35 Million To Hospitals In Nigeria
Caption-Drug Donation to Obio Cottage in Port Harcourt, Rivers State.

Mr. Rockson disclosed that the donation is the company’s way of giving back to society and is in line with their mission to build an Africa that is in good health. He stated that the primary goal of this CSR initiative was to ease the burden of patients and encourage treatment adherence, particularly for those suffering from chronic diseases who are grappling with the rising cost of medications, amongst other challenges. “The drugs will be provided at zero cost to patients unable to pay for their medications at the point of care,” he said.

A total of 44 hospitals across the four states will receive the donations, including General Hospital Alimosho, General Hospital Isolo, Lagos, Ace Medicare Hospital, Otta, and Obio Cottage Hospital, Port Harcourt. Other hospitals to benefit from this donation also include R-Jolad Hospital Lagos, Covenant University Hospital Otta, Sadol Healthcare, Ancilla Catholic Hospital, Moshalasi Community Hospital, Light Hospital & Maternity, Bells University Hospital, Maciland Medical Center, Fortress Health Consultant, St Nicholas Hospital, Etta Atlantic Memorial Hospital, ECWA Comprehensive Medical Center, St. Many Catholic Hospital FCT., Jikwoyi Medical Center Abuja, Arubah Family Medical Center, Cornelia Connelly Catholic Hospital and Westend Specialist Hospital Warri.

Know More About Pharma: mPharma is a patient-centered technology-driven healthcare company. They provide innovative solutions, including vendor-managed inventory services, retail and primary care solutions for community pharmacies, and data analytics. Our mission is to build an Africa in good health by increasing drug access for all patients at reduced costs while assuring and preserving quality. Founded in 2013 and headquartered in Ghana, we have expanded our operations to 8 other African countries, Nigeria, Zambia, Kenya, Rwanda, Ethiopia, Gabon, Togo, and Uganda. We currently have a network of over 400 pharmacies in our key markets, serving more than 100,000 patients each month. Our partner pharmacies across Africa have dispensed millions of life-saving drugs to patients.

Continue Reading

Health

CACPP Seeks Collaboration In The Fight Against Counterfeit Pharmaceutical Products

Published

on

CACPP Seeks Collaboration In The Fight Against Counterfeit Pharmaceutical Products

By Moninuola Sulaiman

The Coalition Against Counterfeit Pharmaceutical Products (CACPP) an umbrella body in conjunction with Nigerian Representatives of Overseas Pharmaceutical Manufacturers (NiroPharm) and Pfizer is leading the charge in seeking collaborations between relevant stakeholders in the pharmaceutical industry in the fight against counterfeit pharmaceutical products in Nigeria.

To this end, CACPP invited relevant stakeholders in Nigeria to the inaugural forum of the Coalition Against Counterfeit Pharmaceutical Products to discuss the way forward in the fight against Counterfeit Pharmaceutical Products on the 28th of November, 2022 at the Protea Hotel by Marriot in Ikeja.

The convener, Yomi Badejo-Okusanya (YBO) while speaking on what informed his decision to form the coalition, said “It is borne out of the desire to take a firmer stand against counterfeit pharmaceutical products in Nigeria through engagement and advocacy, with hope to kick off an intense national advocacy campaign against counterfeit pharmaceutical products.”

Olayinka Subair West Africa Country Manager at Pfizer commented “Counterfeit medicines don’t cure any disease, rather they put patients’ health at risk because of their contents, it ultimately impedes the Nigerian Healthcare System. Lives are lost and medical conditions are worsened due to this cankerworm. It is not an individual’s battle; it requires collective effort.”

He emphasized that “Nigerians need to champion the anti-counterfeit cause, especially as regards healthcare. We need to join hands together because there is no shortcut to health. Due process must be followed to get the best results. Unlike commodities, fake drugs are life-threatening. This means patients should only buy prescribed medicines from accredited pharmacies and not quacks or roadside vendors.”

CACPP Seeks Collaboration In The Fight Against Counterfeit Pharmaceutical Products
Left-Right: Director, Pharmaceutical Council of Nigeria (PCN), Lagos Zonal Office, Dr. Ukamaka Okafor; Group Managing Director, CMC Connect Limited, Yomi Badejo-Okusanya; West Africa Country Manager, Pfizer, Mr. Olayinka Subair; Nollywood Actor and Film Producer, Ayo Badmus; Deputy Director, Federal Task Force on Counterfeit Substandard Regulated Products Investigation and Enforcement – NAFDAC, Pharm. Uba Florence; National Treasurer, Pharmaceutical Society of Nigeria, Pharm. Gafar Lanre Madehin; President, Nigerian Representatives of Overseas Pharmaceutical Manufacturers (Niropharm), Femi Soremekun and Country Manager -Nigeria, Astrazeneca, Morris Nyarko during the inaugural forum for the Coalition Against Counterfeit Pharmaceutical Products (CACPP) in Lagos on 28th of November 2022.

A recent report by Punch Newspaper noted that the prevalence of fake drugs is a menace to over 200 million people in Nigeria 1.

Femi Soremekun, NIROPHARM President stated “In recent years, the fight against counterfeit pharmaceutical products has taken new dimensions due to the global influx of counterfeiting syndicates, it is like a race against time for pharmaceutical companies – the cost to our collective health and economies is enormous.

Over the years, pharmaceutical companies are perplexed as to how best to nip the challenges in the bud. The challenges are overwhelming owing to the sophistication of the activities of counterfeiters.

Combating counterfeit pharmaceutical products is a herculean task, one that requires strong collaborations between government agencies and key stakeholders because of the impact.”

For most African Nations, combating counterfeit pharmaceutical products is even more challenging due to the lack of synergy between key stakeholders in the pharmaceutical industry and government agencies.

To combat the illicit trade of counterfeit pharmaceutical products, there is a strong need for collaboration. Stakeholders must look beyond the surface which is most times in-ward – they must look at the root cause which in most cases boils down to (Identity) or patent, what marks counterfeit from original pharmaceutical products.

The Organization for Economic Co-operation and Development (OECD) and the European Union Intellectual Property Office (EUIPO) in a recent study titled “Trade in Counterfeit Pharmaceutical Products” opined that “The consequences for the economy and for citizens are serious. Trade in counterfeit goods not only damages economic growth but also undermines good governance, the rule of law, and citizens’ trust in government, and can ultimately threaten political stability. In addition, in some cases, such as that of fake pharmaceuticals, counterfeit goods can have serious health and safety implications for citizens.

1.https://punchng.com/how-fake-drugs-threaten-nigerias-multi-billion-pharma-industry/

2.https://doi.org/10.1787/a7c7e054-en.

Continue Reading

Health

NLNG Boost Healthcare Delivery, Begins Commissioning Of Completed University Teaching Hospital Projects In 12 States

Published

on

NLNG Boost Healthcare Delivery, Begins Commissioning Of Completed University Teaching Hospital Projects In 12 States

Olushola Okunlade Writes

Nigeria LNG (NLNG) Limited today began the commissioning of Phase 1 projects in its multi-billion-naira Hospital Support Programme (NLNG HSP) with the opening of a maternity centre at the University of Abuja Teaching Hospital (UATH), Gwagwalada.

The Company will also commission new Intensive Care Units (ICUs) at the University of Benin Teaching Hospital (UBTH) and the Niger Delta University Teaching Hospital (NDUTH) in 2022 as part of the first phase of its HSP program. Six hospitals were selected in the first phase. The NLNG HSP targets 12 hospitals from the six geographical zones in the country.

Other projects in the first phase due for commissioning in early 2023 include an Occupational Therapy and Neuromodulation Rehabilitation Centre at the Aminu Kano Teaching Hospital (AKTH), an Obstetrics & Gynecology Ward at the Lagos University Teaching Hospital (LUTH), and a Neurosurgical & Stroke Centre at the University of Calabar Teaching Hospital (UCTH).

Dignitaries at the event include the Minister of Health, Dr. Osagie Ehanire, represented by the Director of Hospital Services, Dr. B.O Alonge; NLNG’s Managing Director and Chief Executive Officer, Dr. Philip Mshelbila; NLNG’s Deputy Managing Director, Mr. Olalekan Ogunleye; UATH Chief Medical Director, Professor Bissallah Ekele; Chairperson, Senate Committee on Women Affairs, Senator Betty Apiafi; Chairman House of Representative Committee on Health, Honourable Yusuf Tanko Sununu; the General Manager, External Relations and Sustainable Development, NLNG, Mr. Andy Odeh, among others.

Commissioning the maternity centre, Minister of Health, Dr. Osagie Ehanire, commended NLNG for the partnership and commitment to raising the level of healthcare delivery in the country. He said NLNG’s contribution of a Modern Maternity and Child Centre to UATH was in line with the principles of universal health coverage. He also called for more partnerships in the sector to fill gaps in healthcare delivery.

NLNG Boost Healthcare Delivery, Begins Commissioning Of Completed University Teaching Hospital Projects In 12 States
Chairperson, Senate Committee on Women Affairs, Senator Betty Apiafi; Chairman House of Representative Committee on Health, Honourable Yusuf Tanko Sununu; UniAbuja Teaching Hospital (UATH) Chief Medical Director, Professor Bissallah Ekele; NLNG’s MD/CEO, Dr. Philip Mshelbila; the Aguma of Gwagwalada, HRM Alhaji Mahammadu Magaji; and NLNG’s Deputy MD, Olalekan Ogunleye at the commissioning of a modern maternity centre as part of the NLNG Hospital Support Programme in Abuja…on Friday.

Speaking on NLNG’s commitment to Hospital Support Programme, NLNG’s MD, Dr. Philip Mshelbila, said the program was conceived following the Company’s COVID-19 intervention and its concern over the increasing pressure on the healthcare facilities in the country. He stated that the goal of the project was to boost the tertiary healthcare delivery system in 12 University Teaching Hospitals in the 6 geopolitical zones in the country, with attendant impacts on medical research and retention of in-country medical expertise.

“First hand, we have seen how investment in the health sector can change the face of healthcare delivery in Nigeria. We contributed significantly to fighting COVID-19 through the NNPC and other Oil and Gas Industry Partner COVID-19 Intervention Programme by donating numerous intensive care medical equipment to medical facilities across the country. At the Federal Medical Centre Yola, for instance, the equipment came in handy for successfully separating a set of conjoined twins. This feat brought us at NLNG a lot of satisfaction as we saw the impact our donation made in the lives of those innocent children and others who would utilise the equipment. We believe we can expand this impact by investing more in facilities across the country,” he said.

He stated further that each facility in the program was based on the results of needs analyses carried out in conjunction with the respective hospitals, to determine NLNG’s intervention area for each of the chosen Teaching Hospitals.

The newly commissioned UATH Maternity Centre consists of a 10-bed delivery suite, a 10-bed post-natal ward, two operating theatres, 10-bed Special Care Baby Unit (SCBU), consulting rooms, doctors and nurses’ rooms, a laboratory, a pharmacy, medical records office, a Close-Circuit Television (CCTV) system, Ultrasound scan room, and other administrative offices.

The NLNG HSP is the second part of NLNG’s national Corporate Social Responsibility (CSR) initiative. The first part was the University Support Programme (USP) for the construction/rehabilitation of modern engineering laboratories, equipped with cutting-edge equipment in six universities which have since been completed.

The other six university teaching hospitals to benefit from the HS Programme in Phase Two in 2023 through 2024 are Abubakar Tafawa Balewa University Teaching Hospital (ATBUTH), Bauchi; Jos University Teaching Hospital (JUTH); Nnamdi Azikiwe University Teaching Hospital (NAUTH), Nnewi; Federal Medical Centre, Asaba; University of Uyo Teaching Hospital (UUTH); and University of Port Harcourt Teaching Hospital (UPTH) in Rivers State.

NLNG is an incorporated Joint Venture owned by Federal Government of Nigeria, represented by Nigerian National Petroleum  Company (49%), Shell Gas B.V.  (25.6%), TotalEnergies Gaz & Electricite Holdings (15%), and Eni International N.A. N. V. S.àr.l (10.4%).

Continue Reading

Trending